Moreover, the sequential treatment of Huh7 cells with rapamycin, an mTOR inhibitor, following treatment with sorafenib substantially increased the sensitivity of HCC cells to sorafenib and decreased the frequency of liver cancer stem cell (CSC)-like cells, which are considered primary cells resistant to chemotherapy [52]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.